Hypoxia, a common feature of human cancers, is often associated with poor prognosis (Brown and Wilson, 2004). Impaired drug penetration into hypoxic regions of tumours was thought to explain the poor prognosis, but recently an adaptive cellular response to hypoxia was demonstrated to reduce the cytotoxicity of many drugs. A central component of hypoxic adaptation is the stabilisation and activity of hypoxia-inducible factor-1 (HIF-1). Hypoxia-inducible factor-1 orchestrates the transcriptional regulation of genes involved in a plethora of cellular processes, including glycolysis, angiogenesis, metastasis and chemo-resistance (Moeller et al., 2004; Williams et al., 2005; Brown et al., 2006; Moeller and Dewhirst, 2006). Consequently, HIF-1 is perceived as a tractable drug target (Stratford et al., 1994; Williams et al., 2004; Semenza, 2007), and novel anticancer agents targeted to HIF-1-modulated pathways are being evaluated for clinical use. Multicellular spheroids that model the hypoxic microenvironment in vivo can be exploited to achieve a more comprehensive assessment of factors contributing to resistance of hypoxic cells within tumours (Jones et al., 1982; West et al., 1984; Olive et al., 1996). Moreover, isolation of cell sub-populations from different spheroid microenvironments allows a detailed mechanistic study (Olive et al., 1996). Here, monolayer and spheroids of HCT116 colorectal cancer (CRC) cells treated with oxaliplatin were compared with discrete contributions of drug bioavailability (reported by DNA adducts), hypoxia and HIF-1 function(s) to the cellular response to a clinically relevant therapy for CRC.

MATERIALS AND METHODS

All materials were from Sigma-Aldrich (Gillingham, UK) unless otherwise stated.
Cell culture and drug treatment

HCT116 human CRC cells were cultured under standard conditions and were considered hypoxic for a minimum of 8 h before drug treatment (details in supplementary methods). Spheroids were formed as detailed in supplementary methods. Spheroids (~50) were placed into 3.6 ml cryotubes (Nunc, Fisher Scientific, Loughborough, UK) with 1 ml media containing drug or vehicle. The tubes were gassed with 5% CO2/air, sealed and incubated at 37°C on a Stuart roller mixer device (VWR International, Lutterworth, UK). Oxaliplatin (Alexis Biochemicals via Axxora (UK) Ltd, Birmingham, UK) was prepared as a 10 mM stock solution in PBS, stored as aliquots at −80°C, and was only subjected to a single freeze-thaw cycle. To treat spheroids or cells, the stock solution was diluted in media to the appropriate concentration.

Generation and validation of cell lines to investigate HIF-1α

The coding sequence of a dominant-negative (DN) HIF-1α construct (Brown et al. (2006) was cloned into pEFIRESp (Hobbs et al., 1998). Growing phase HCT116 or HT1080 cells were transfected with DN or empty vector (EV) using lipofectamine according to the manufacturer’s instructions (Invitrogen, Paisley, UK), with puromycin added 48 h later. Resistant colonies were expanded and HIF function was assessed by HRE reporter assay (Brown et al., 2006). Further validation was carried out by immunoblotting cell extracts obtained after aerobic or hypoxic conditions for HIF-1α and the HIF-1 downstream target glucose transporter-1 (GLUT-1) using the following primary antibodies: HIF-1α (1:500; BD Transduction Laboratories, Oxford, UK), GLUT-1 (1:6000, AB1340, Chemicon, Watford, UK) and β-actin (1:80000; Sigma—Aldrich), followed by horseradish peroxidase-coupled secondary IgG with resolution by enhanced chemiluminescence.

Cells reporting HIF function were generated by transfecting HCT116 cells with an LDH-HRE-SV40 min-luciferase construct in pCI-neo and selecting stable colonies after G418 exposure. Colonies exhibiting robust HRE-mediated luciferase induction after hypoxic exposure were transfected with pEFIRESp encoding renilla luciferase, selected using puromycin and monitored for normal renilla luciferase activity following the manufacturer’s guidelines (Promega, Southampton, UK).

Immunohistochemistry

Spheroids were fixed in 4% buffered formalin overnight at 4°C and paraffin embedded. Sections were cut (~4 μm) and immunostaining was performed after dewaxing in xylene and rehydration in graded alcohols. Antigen retrieval was carried out by microwaving (800 W, 20 min) and cooling (15 min) in 10 mM citrate buffer, pH 6.0. Sections were blocked (0.1% Trit-HCL, 0.15 mM NaCl, pH 7.5, 4% normal goat serum (Dako, Glostrup, Denmark) for 2 h and incubated overnight at 4°C with primary antibody or antibodies: cleaved caspase-3, (1 in 100, CC3, Cell Signalling Technologies, Inc.) with 5% CO2/air, sealed and incubated at 37°C on a Stuart roller mixer device (VWR International, Lutterworth, UK). Oxaliplatin (Alexis Biochemicals via Axxora (UK) Ltd, Birmingham, UK) was prepared as a 10 mM stock solution in PBS, stored as aliquots at −80°C, and was only subjected to a single freeze-thaw cycle. To treat spheroids or cells, the stock solution was diluted in media to the appropriate concentration.

Fluorescence-activated cell sorting

Spheroids were washed with fresh media and incubated (20 min, 37°C) with 10 μM Hoechst 33342 (Invitrogen). After a PBS wash, spheroids were dissociated with trypsin (Invitrogen, 0.5%, 10 min), centrifuged and resuspended in fresh media at 107 cells ml−1 before sorting into four fractions on the basis of Hoechst 33342 fluorescence using a BD FACSAria (Becton Dickinson, Oxford, UK). Debris was gated out and the brightest (B) and dimmest (D) 15% cells were sorted, with the remaining cells being equally distributed into medium-dim (MD) and medium-bright (MB) fractions. Sorted fractions were plated for clonogenic survival, assayed for luciferase activity (reporter cell lines) or used for determination of platinum (Pt) adduct levels after drug treatment. The oxaliplatin concentration required to kill 90% cells in each sorted sub-population was compared with that required to kill 90% of the bright (B), outermost fraction. A relative resistance value was calculated as the dose modification factor (DMF) for 90% cell kill (ratio of dose required to kill 90% cells in the inner-fractions compared with that in the B fraction).

Oxaliplatin adduct quantification

Total intracellular Pt levels were determined from monolayers or from sorted spheroid sub-populations. Cells were resuspended in ice-cold 10 mM Tris-HCl, 1% Triton-X100 pH 7.5 containing protease inhibitor cocktail and were sonicated to lyse cells and fragment DNA. Proteins were hydrolysed with NaOH and the remaining DNA was hydrolysed with nitric acid. Samples were stored at −80°C. Nitric acid (67–70%) was Optima grade for trace metal analysis (Fisher Scientific). Cellular Pt content was determined using a magnetic sector ICP-MS (Thermo Element 2) with a low uptake nebuliser. To correct for and measure any signal suppression due to sample matrix effects, all standards, blanks and samples contained thallium (Tl) as internal standard; hafnium (Hf) was also monitored as described previously (John et al., 2003). Platinum concentrations were derived by reference to a standard solution calibration curve using the mean concentration from the three Pt isotopes.

Statistical analysis

Two-tailed t-tests were used to evaluate significant differences. P-values of <0.05 were considered as statistically significant.

RESULTS

Previous studies established that CRC cells resist a number of chemotherapeutics under hypoxic conditions (Erler et al., 2004). In this study, hypoxic HCT116 cells were found to be resistant to oxaliplatin using short-term SRB (IC50 normoxia = 5.2 μM vs IC50 hypoxia = 10.1 μM, P = 0.015) and clonogenic survival end points.
Oxaliplatin response in colorectal cancer spheroids

DL Roberts et al

Figure 1 Hypoxia-induced oxaliplatin resistance. HCT116 cells were exposed to normoxia or hypoxia for 8 h and were treated with oxaliplatin (0–25 μM) for 16 h under continued normoxia or hypoxia. Clonogenic survival was assessed 6–10 days later. The surviving fraction was determined from the mean of two experiments, each containing a range of cell densities in duplicate.

(IC50 normoxia 2.4 μM vs IC50 hypoxia 5.9 μM; Figure 1). The IC50 for oxaliplatin under hypoxia was 1.9- and 2.4-fold higher than that in normoxia for SRB and clonogenic assays, respectively.

Hypoxic cells within multicellular CRC spheroids were oxaliplatin resistant

To investigate cellular response to chemotherapy in a more physiologically relevant model, HCT116 cells were grown as three-dimensional spheroids. Figures 2A and B show that untreated spheroids have a high proportion (>90%) of proliferating cells (Ki67 positive), except in peri-necrotic regions (<15% positive), whereas apoptosis (CC3 positivity) was observed in <10% cells (n = 10). Treatment with 5–10 μM oxaliplatin decreased Ki67 staining. At 25 μM, oxaliplatin increased Ki67 staining, a paradoxical result most likely explained by nuclear fragmentation. An oxaliplatin concentration-dependent increase in CC3 staining was observed to be restricted to the outer rim, suggesting that response of inner cells may be dependent on their oxygenation and nutrient status and/or drug penetration through the cell mass. Similar results were observed using dual staining; Ki67 stained in outer and peri-necrotic regions, whereas CC3 was only evident in outer regions (Figure 2B). Staining specificity was ascertained using MCF-7 cell pellets (caspase-3 null) and staurosporine-treated HUVEC cells as negative and positive controls, respectively.

To investigate the relationship between proliferation, cell death and cellular location, staining was repeated on oxaliplatin-treated spheroids using immunofluorescent detection for direct comparison of respective biomarkers (Figure 2B and C). Ki67 staining decreased significantly towards the necrotic core (the outermost 10% of the spheroid compared with the innermost 10%, P < 0.0001), and this pattern did not change with oxaliplatin treatment. Staining for CC3 was significantly higher in the outer 50% cells within treated spheroids (P < 0.0001) compared with the inner 50%. Cell sub-populations were isolated to assess any relationship between histology and cell survival. After exposure to oxaliplatin for 1 h, spheroids were treated with Hoechst 33342, disaggregated and sorted into four sub-populations: bright (B), medium-bright (MB), medium-dim (MD) and dim (D). Those cells with high fluorescence (B) come from the outer, well-oxygenated regions, whereas cells showing low fluorescence (D) arise from inner, hypoxic regions (Olive et al., 1985). Consistent with the immunohistochemistry analysis, Figure 3A shows that B and MD sub-populations had significantly increased IC50 values compared with D sub-population cells (values were calculated from raw data for each experiment and averaged to give IC50 (D), 19.67 μM, (MD) 17.45 μM compared with (B) 13.0 μM, P < 0.0001). Increasing oxaliplatin exposure from 1 to 24 h revealed a similar trend (data not shown). These data also demonstrate that culture of cells in a three-dimensional system alters their response to oxaliplatin, as revealed by comparing the outer cell response to that of control monolayers; this reveals that cells grown in three dimensions are inherently more resistant (B sub-population IC50, 13 μM, control monolayer IC50, 2.4 μM).

Reduced drug uptake/retention in hypoxic cells within spheroids did not account fully for reduced cytotoxicity

To investigate whether the change in cell survival throughout spheroids was due to differential oxaliplatin bioavailability, Pt-adduct formation was analysed in sorted sub-populations using Inductively Coupled Plasma Mass Spectroscopy (ICP-MS; Table 1). After exposure to oxaliplatin (25 μM, 2 h), cells were sorted into D, MD and B sub-populations and adducts were expressed as % Pt-adducts in the B sub-population. Adduct formation was reduced by 1.3-fold and 1.5-fold in MD and D cells, respectively, with that observed in the B sub-population. However, survival was increased after exposure to oxaliplatin from SF 0.02 for the B sub-population to 0.157 for MD and 0.22 in D sub-populations (increasing 7.8-fold from B to MD and 11-fold from B to D, Figure 3A).

To investigate whether the observed changes in Pt-adduct formation merely reflected oxaliplatin penetrance through spheroids, HCT116 monolayers were treated with oxaliplatin, and adduct formation was analysed after 21 or 1% oxygen exposure. Interestingly, adduct formation was also reduced significantly in hypoxia (P = 0.013 at 10 μM, P = 0.026 at 25 μM) in which there was no biophysical hindrance to drug exposure (Figure 3B). Taken together with relative survival data (Figure 3A), this suggests that mechanisms other than drug penetration contribute to oxaliplatin resistance in hypoxic cells within spheroids.

Monolayer cultures of HCT116 that lack HIF function did not show hypoxic resistance to oxaliplatin

Our previous studies using monolayers implicated HIF-1 in hypoxic resistance to chemotherapeutics (Erler et al., 2004; Brown et al., 2006). To facilitate the extrapolation of these observations to spheroids, stable HCT116 cell lines were generated to express a DN variant of HIF-1α (Brown et al., 2006). Control cells expressed an EV. Expression of DN HIF-1α ablated HIF-1-mediated reporter gene expression after exposure to cobalt chloride (Figure 4A), as well as the expression of the HIF-1 target GLUT-1 (Figure 4B). Expression of native HIF-1α protein was unaffected by the DN variant, but hypoxia-induced expression of GLUT-1 was absent from DN cells grown as monolayers or as spheroids (Figure 4B and C). In EV spheroids, GLUT-1 localised to the hypoxic, peri-necrotic areas corresponding to regions labelled by the hypoxia biomarker pimonidazole (Figure 4C, data not shown). Glucose transporter-1 staining was not seen in hypoxic regions of DN spheroids (Figure 4C). Exposure of monolayer EV cells to oxaliplatin revealed hypoxic resistance by SRB assay (Figure 5A), which matched that of parental cells (IC50 hypoxia/IC50 air 1.4-fold, not shown). However, no hypoxic resistance to oxaliplatin was observed in DN cells, demonstrating an HIF-1-dependent resistance mechanism (Figure 5A). Similar results were observed on inhibition of HIF-1 function through DN expression in HT1080 human fibrosarcoma cells exposed to 5 μM oxaliplatin for 24 h (Supplementary Figure 1).

The differences in response between HCT116 cells with and without functional HIF was independent of oxaliplatin uptake

To ensure that changes in oxaliplatin sensitivity were not due to differential drug uptake between EV and DN cells, Pt-adducts...
formation was assessed in monolayers exposed to a range of oxaliplatin concentrations under normoxia or hypoxia (Figure 5B). A concentration-dependent increase in protein-Pt-adduct formation was revealed in EV and DN cells under both conditions. The adduct formation was reduced in hypoxia vs normoxia for both cell lines, consistent with data from untransfected cells (Figure 3), suggesting that modification of oxaliplatin uptake/retention under hypoxic conditions is independent of HIF function.

Lack of HIF function ablated hypoxic resistance to oxaliplatin in cells derived from spheroids

Oxaliplatin sensitivity was investigated in sorted sub-populations of EV and DN spheroids. Initial studies were undertaken to validate whether sub-populations showed differences in HIF activity using spheroids of HCT116 HIF-1 reporter cells. These cells express firefly luciferase under the transcriptional regulation of HIF-1 (through inclusion of a trimer sequence of the lactase...
dehydrogenase promoter) and a renilla luciferase construct under the regulation of the strong constitutive promoter elongation factor-1α. The expression level of firefly luciferase relative to renilla luciferase in each sub-population was compared with that obtained from whole-spheroid lysates (Figure 6A). The relative level of HIF-1-driven firefly luciferase expression compared with that of renilla luciferase was 56% lower in the outer spheroid regions compared with the inner region (D), and increased in a step-wise manner to the inner regions (Figure 6A), confirming that spheroid sub-populations differed in their HIF-transactivation levels.

Empty vector and DN spheroids were exposed to oxaliplatin after sorting to exclude potential changes in penetrance that could confound HIF-mediated effects. The response of the outer two fractions (B and MB) was almost identical for both cell types (Figure 6B and C), with greater sensitivity observed in outermost cells. However, whereas the inner two sub-populations (D and MD) of EV spheroids showed resistance to oxaliplatin treatment, this was not apparent in DN cells isolated from the same sub-populations. Relative resistance factors were calculated for the sub-populations by determining the DMF required for 90% kill compared with that of the B sub-population. The DMFs for MB, MD and D populations were 1.4, 1.9 and 2.1, and 1.3, 1.4 and 1.4 for the EV- and DN-derived spheroid populations, respectively (Figure 6B and C, data not shown). As during this experiment cells were re-oxygenated during the period of drug exposure, we investigated how re-oxygenation affected the hypoxia-induced changes in the levels of GLUT-1 (upregulated by HIF-1) and Bax (repressed by hypoxia independent of HIF-1) at the protein level (Supplementary Figure 2). This revealed that changes in protein levels were maintained for 8–12 h on re-oxygenation, indicating that our sorted fractions maintained a hypoxic ‘phenotype’ during post-sort drug exposures.

**DISCUSSION**

This study investigated oxaliplatin sensitivity in HCT116 CRC cells using both monolayers and spheroids to identify relative contributions of physical vs biological mechanisms of hypoxic resistance to chemotherapy. In monolayers, in which issues of exposure and biodistribution are eliminated, oxaliplatin was less effective in hypoxic compared with aerobic cells. Interestingly, Pt-adduct formation was reduced markedly in hypoxic cells exposed to oxaliplatin, which could contribute to the observed differential toxicity. Treatment of cells with oxaliplatin at concentrations greater than clonogenic IC₅₀ suggested that apoptosis was dependent on the generation of reactive oxygen species (Berndtsson et al, 2007), which would be compromised in hypoxia. Consistent with data from monolayers, sensitivity to oxaliplatin treatment was greater in cells of the outer, better-oxygenated regions of HCT116 spheroids. Oxaliplatin provoked concentration-
dependent increases in apoptosis in outer regions, whereas it had minimal impact on proliferation throughout the spheroid. When spheroids were fractionated after oxaliplatin treatment, clonogenic survival observed in outer region cells was eightfold higher than that in innermost cells. The difference in Pt-adduct formation between these two sub-populations was lower (1.5-fold reduction). This suggests that compromised bioavailability was not the major mechanism underpinning the poorer response of hypoxic cells to oxaliplatin treatment. Furthermore, it suggests that in more physiologically relevant culture models, cellular ‘handling’ of oxaliplatin is markedly different to that observed in monolayers and that in these models, adduct formation is not a reliable biomarker for cytotoxicity per se.

In this study, a genetic approach was used to inhibit HIF-1 function in HCT116 cells by the introduction of a DN HIF-1α subunit. Oxaliplatin was equitoxic to control monolayers of DN or EV cells. However, whereas hypoxia induced resistance in EV cells, in DN cells hypoxic sensitivity was equivalent to that in air. Oxaliplatin adduct formation was unaltered by ablated HIF function. In fractionated spheroids, the outermost cells exhibited similar responses to oxaliplatin (SF 10 μM oxaliplatin 0.061 EV vs 0.066 for DN), consistent with monolayers. However, cells from the inner regions of DN spheroids were more sensitive than were their EV counterparts. The level of sensitisation within spheroid

**Table 1** Distribution of platinum (Pt)-adduct formation in HCT116 spheroids

|          | Bright | Medium-bright | Medium-dim | Dim |
|----------|--------|---------------|------------|-----|
| Percentage (%) Pt | 100    | 95.994        | 76.361     | 66.020 |
| s.e.     | —      | 4.615         | 8.839      | 4.333  |
| P-value vs bright | —      | 0.4344        | 0.0555     | 0.0014 |

**Figure 3** Effect of oxaliplatin on cell survival in spheroids and quantification of platinum adducts. Spheroids were treated with oxaliplatin (0–25 μM) for 1 h and then fractionated. Clonogenicity was determined and the surviving fraction plotted for each sub-population and oxaliplatin concentration (A). Monolayer samples were assessed for total platinum levels by ICP-MS (B). Platinum values are given as fmoles mg⁻¹ protein. Data are the mean of three experiments (± s.e.).

**Figure 4** Validation of the HCT116 DN model. HCT116 cells were stably transfected with an empty vector cassette (EV) or an hypoxia-inducible factor (HIF)-α dominant-negative construct (DN). Altered HIF-1 function was validated using an HIF reporter assay analysed in the presence or absence of hypoxia mimetic cobalt chloride (A) and by immunoblot analysis of the HIF-1 target glucose transporter-1 (GLUT-1) (B). At ~500 μM, HCT116 wild type, EV or DN spheroids were treated with 100 μM pimonidazole, fixed, sectioned and immunostained for GLUT-1 and pimonidazole adducts (C). Data are from a representative experiment showing the mean ± s.d. of triplicate samples (A); immunoblots (B) and immunostaining (C) are representative of three separate experiments. Scale bars indicate 100 μm.
sub-populations correlated with HIF-1 activity determined using fractionated sub-populations from HCT116 cells expressing an HIF-1 responsive-luciferase reporter.

Taken together, these data suggest that HIF-1 has an important role in mediating oxaliplatin sensitivity in HCT116 cells. Given our previous findings, as well as those of others, hypoxic cell chemoresistance is predicted to be a strong contributor to the poor response of CRC to standard therapies. A potential contribution of HIF-1 to this phenotype is supported by clinical studies demonstrating HIF-1α expression as a poor prognostic indicator in CRC (Lu et al., 2006). The mechanisms by which HIF-1 contributes to resistance are likely to be complex and varied depending on cell genotype. Indeed, recent data observing sensitisation to cisplatin using HIF-targeting RNAi suggest that reversal of hypoxic resistance is p53 dependent (Hao et al., 2008). We previously reported that HIF-1 can alter the balance of pro- and anti-apoptotic proteins under hypoxic conditions (Erler et al., 2004). Specifically, HIF-1 can downregulate pro-apoptotic Bid, the reversal of which is associated with enhanced chemotherapy response (Brown et al., 2006). The reciprocal relationship between HIF-1α and Bid expression is maintained in clinical samples of CRC, supporting its potential importance (Seenath et al., 2008).

With current interest in the development of HIF-targeting agents as novel cancer therapies, these data would support their exploitation in combination with standard chemotherapy to enhance the treatment response in CRC.

ACKNOWLEDGEMENTS

This work was supported by a CR-UK project grant to IJS, CD and KJW (C84/A4394) and by programme support from MRC (IJS and KJW, G0500366) and CR-UK (CD, CI47/A6058). We thank Gary Ashton and Caron Abbey (Histology Service, Paterson Institute), Mike Hughes and Jeff Barry (FACS Service, Paterson Institute) and Steve Bagley (Advanced Imaging Facility, Paterson Institute).

Conflict of interest

The authors declare no conflict of interest.

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES

Berndtsson M, Hägg M, Panaretakis T, Havelka A, Shoshan M, Linder S, (2007) Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. *Int J Cancer* 120: 175 – 180

Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. *Nat Rev Cancer* 4: 437 – 447

Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, Sheppard FCD, Parker CA, Stratford IJ, Williams KJ (2006) Reversing hypoxic cell chemoresistance in *vitro* using genetic and small molecule approaches targeting hypoxia inducible factor-1. *Mol Pharmacol* 69: 411 – 418

Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ, Dive C (2004) Hypoxia-mediated down-regulation of bid and bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. *Mol Cell Biol* 24: 2875 – 2889

Hao J, Song X, Song B, Liu Y, Wei L, Wang X, Yu J (2008) Effects of lentivirus-mediated HIF-1[alpha] knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. *Cancer Gene Ther* 15: 449 – 455

Hobbs S, Jitrapakdee S, Wallace JC (1998) Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1[alpha] promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. *Biochem Biophys Res Commun* 252: 368 – 372

John T, Ottley CJ, Pearson DG, Nowell GM, Calvert AH, Tilby MJ (2003) Determination by ICP-MS, of background and BBR 3464 induced levels of platinum bound to DNA isolated from blood cells: A comparison of the sensitivity of the Perkin Elmer Sciex Elan 6000 and the Thermo-Finnigan Neptune Instruments. In *Plasma Source Mass Spectrometry*, Holland JG, Tanner SD (eds), pp 82 – 91. Royal Society of Chemistry; Cambridge, UK

Jones AG, Stratford IJ, Wilson PA, Peckham MJ (1982) *In vitro* cytotoxic drug sensitivity testing of human tumour xenografts grown as multicellular tumour spheroids. *Br J Cancer* 46: 870 – 879

Lu XG, Xing CG, Feng YZ, Chen J, Deng C (2006) Clinical significance of immunohistochemical expression of hypoxia-inducible factor-1alpha as a prognostic marker in rectal adenocarcinoma. *Clin Colorectal Cancer* 5: 350 – 353

Moeller BJ, Cao Y, Li CY, Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. *Cancer Cell* 5: 429 – 441

Moeller BJ, Dewhirst MW (2006) HIF-1 and tumour radiosensitivity. *Br J Cancer* 95: 1 – 5

Olive PL, Chaplin DJ, Durand RE (1985) Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. *Br J Cancer* 52: 739 – 746

Olive PL, Vilke CM, Banath JP (1996) Use of the comet assay to identify cells sensitive to tirapazamine in multicell spheroids and tumors in mice. *Cancer Res* 56: 4460 – 4463

Seenath MM, Roberts D, Cawthorne C, Saunders MP, Armstrong GR, O’Dwyer ST, Stratford IJ, Dive C, Renehan AG (2008) Reciprocal relationship between expression of hypoxia inducible factor 1[alpha] (HIF-1[alpha]) and the pro-apoptotic protein Bid in *ex vivo* colorectal cancer. *Br J Cancer* 99: 459 – 463

Semenza GL (2007) Evaluation of HIF-1 inhibitors as anticancer agents. *Drug Discovery Today* 12: 853 – 859

Stratford IJ, Adams GE, Bremner JC, Cole S, Edwards HS, Robertson N, Wood PJ (1994) Manipulation and exploitation of the tumour environment for therapeutic benefit. *Int J Radiat Biol* 65: 85 – 94

Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. *Nat Protocols* 1: 1112 – 1116

West CM, Sandhu RR, Stratford IJ (1984) The radiation response of V79 and human tumour multicellular spheroids–cell survival and growth delay studies. *Br J Cancer* 50: 143 – 151

Williams KJ, Cowen RL, Brown LM, Chinje EC, Jaffar M, Stratford IJ (2004) Hypoxia in tumors: molecular targets for anti-cancer therapeutics. *Adv Enzyme Regul* 44: 93 – 108

Williams KJ, Telfer BA, Airley RE, Peters HP, Sheridan MR, van der Kogel AJ, Harris AL, Stratford IJ (2002) A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis. *Oncogene* 21: 282 – 290

Williams KJ, Telfer BA, Xenaki D, Sheridan MR, Desbaillets I, Peters HJW, Honess D, Harris AL, Dachs GU, Kogel Avd, Stratford IJ (2005) Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. *Radiother Oncol* 75: 89 – 98